The treatment typically requires a BMI of 30 or higher, although it is also considered safe for patients under a BMI of 30 who aim to lose 10-15 pounds
Some people experience modest weight loss in the first few months due to appetite suppression, whilst others may gain weight or return to baseline after six months to a year of treatment as the body adjusts or depression symptoms improve
By Indication, Type 2 Diabetes mellitus leads the market, due to high prevalence, strong glycemic control, and clinical benefits Type 2 Diabetes Mellitus (T2DM) dominates the GLP-1 receptor agonist market, with a 61.7% share in 2025 , driven by its high global prevalence
563 Monitoring and considerations include dose titration, initiating medications at low doses and gradually increasing to the maximum tolerated dose while monitoring efficacy and adverse effects
It mimics two gut hormones, GLP-1 and GIP